Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qilu Pharma Launches Biosimilar to AstraZeneca's Iressa in China

publication date: Feb 23, 2017
Qilu Pharma of Jinan has launched its biosimilar version of AstraZeneca's Iressa in China. The biosimilar, a treatment for non-small cell lung cancer that tests positive for the EGRF-TK mutation, will reduce the cost of treating the disease from $1018 to $219 per month. The CFDA approved Qilu's biosimilar, known as Yiruike, in April 2016. Privately owned Qilu produces a portfolio of 160 generic drugs and 100 APIs in several disease areas; oncology is a major focus for the company. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital